Desbalances genómicos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico
PDF

Palabras clave

Linfoma de Hodgkin
FISH
PD-L1/PD-L2
Expresión génica

Cómo citar

Metrebian, M. F., Pavlovsky, A., Slavutsky, I., García Montenegro, M., & Narbaitz, M. (2021). Desbalances genómicos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico. Médicas UIS, 34(1), 35–44. Recuperado a partir de https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/12246

Resumen

Introducción: El linfoma de Hodgkin clásico presenta escasas células de Reed Sternberg/Hodgkin inmersas en un abundante microambiente tumoral. Los desbalances genómicos del locus 9p24.1 han sido asociados con alteraciones en la expresión de los genes del ligando de muerte celular 1 y 2, ambos reguladores de la respuesta inmune. Objetivo: Evaluar desbalances genómicos del locus 9p24.1 en células de Reed Sternberg/Hodgkin y del microambiente tumoral en biopsias de pacientes con linfoma d Hodgkin clásico y correlacionarlo con la expresión del ligando de muerte celular 1 y la presentación de la enfermedad. Materiales y Métodos: Se efectuó hibridación in situ en biopsias de 22 pacientes con linfoma de Hodgkin clásico dirigida a los genes del ligando de muerte celular 1 y 2. Las alteraciones se clasificaron en: amplificación, ganancia y polisomía. La expresión se evaluó mediante inmunohistoquímica. Resultados: Todos los pacientes mostraron alteraciones del número de copias. Se diferenciaron dos grupos: con amplificación (32%) y sin amplificación (68%); este último subdividido en: rico en ganancia (53%) y rico en polisomías (47%). El grupo rico en polisomías mostró mayor edad (p=0,027). El 40% de los pacientes con amplificación y rico en ganancias no presentó masa bulky. La expresión proteica mostró score +3 sólo en estos últimos. El 100% de los casos ricos en polisomías presentaron monosomía del cromosoma 9 en los linfocitos circundantes respecto al 36,4% de los otros dos grupos. Conclusiones: Nuestros datos constituyen un aporte a la caracterización biológica del LHC, de interés en el marco de las nuevas modalidades terapéuticas. 

PDF

Referencias

Shanbhag S, Ambinder RF. Hodgkin Lymphoma: A review and

update on recent progress. CA Cancer J Clin. 2018;68(2):116-

PubMed PMID: 29194581; PubMed Central PMCID:

PMC5842098.

Pavlovsky A, Fernandez I, Kurgansky N, Prates V, Zoppegno L,

Negri P, et al. PET-adapted therapy after three cycles of ABVD

for all stages of Hodgkin lymphoma: results of the GATLA LH-

trial. Br J Haematol. 2019;185(5):865-73. PubMed PMID:

Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and

mortality worldwide: sources, methods and major patterns in

GLOBOCAN 2012. Int J Cancer. 2015;136(5): E359-86. PubMed

PMID: 25220842.

Kusminsky G, Abriata G, Forman D, et al. Hodgkin lymphoma

burden in Central and South America. Cancer Epidemiol.

;44 Suppl 1:S158-67. PubMed PMID: 27678318.

Siegel RL Miller KD, Jemal A. Cancer Statistics, 2019. CA Cancer

J Clin. 2019;69(1):7-34. PubMed PMID: 30620402.

Jaffe ES, Stein H, Swerdlow SH. Classic Hodgkin lymphoma. In:

Swerdlow SH, Campo E, Harris NL, editors. WHO Classification

of Tumors of Hematopoietic and Lymphoid Tissues. Revised 4th

ed. Lyon: IARC Press; 2017. p. 435-42.

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert

R, et al. The 2016 revision of the World Health Organization

classification of lymphoid neoplasms. Blood. 2016;

(20):2375-90.

Hodgkin T. On some morbid appearances of the absorbent glands

and spleen. Med. Chir. Trans. 1832;17:68-114

Mani H, Jaffe ES. Hodgkin lymphoma: an update on its

biology with new insights into classification. Clin Lymph Res.

;9(3):206-16.

Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer.

;9(1):15-27.

Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM,

Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma

after failure of both autologous stem-cell transplantation and

brentuximab vedotin: a multicentre, multicohort, single-arm

phase 2 trial. The Lancet Oncol. 2016;17(9):1283-94.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC,

Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or

refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311-9.

Liu Y, Sattarzadeh A, Diepstra A, Visser L, van den Berg A. The

microenvironment in classical Hodgkin lymphoma: an actively

shaped and essential tumor component. Semin Cancer Biol.

;24:15-22.

Aldinucci D, Celegato M, Casagrande N. Microenvironmental

interactions in classical Hodgkin lymphoma and their role in

promoting tumor growth, immune escape and drug resistance.

Cancer Lett. 2016;380(1):243-52.

Calabretta E, d’Amore F, Carlo-Stella C. Immune and

inflammatory cells of the tumor microenvironment represent

novel therapeutic targets in classical Hodgkin lymphoma. Int J

Mol Sci. 2019;20(21):5503.

Hartmann S, Martin-Subero JI, Gesk S, Husken J, Giefing M,

Nagel I, et al. Detection of genomic imbalances in microdissected

Hodgkin and Reed-Sternberg cells of classical Hodgkin’s

lymphoma by array-based comparative genomic hybridization.

Haematologica. 2008;93(9):1318-26.

Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M,

et al. Genome-wide copy number analysis of Hodgkin Reed-

Sternberg cells identifies recurrent imbalances with correlations

to treatment outcome. Blood. 2010;116(3):418-27.

Cuceu C, Hempel WM, Sabatier L, Bosq J, Carde P, M’Kacher R.

Chromosomal instability in Hodgkin lymphoma: An in-depth

review and perspectives. Cancers. 2018;10(4):91.

Erdkamp FL, Schouten HC, Breed WP, Janssen WC, Hoffmann

JJ, Schutte B, et al. DNA aneuploidy in Hodgkin’s disease: a

multiparameter flow cytometric analysis. Leuk Lymphoma.

;12 (3-4):297-306

Jansen MP, Hopman AH, Haesevoets AM, Gennotte IA, Bot FJ,

Arends JW, et al. Chromosomal abnormalities in Hodgkin’s

disease are not restricted to Hodgkin/Reed-Sternberg cells. J

Pathol. 1998;185(2):145-52.

Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O’Donnell E,

et al. Integrative analysis reveals selective 9p24.1 amplification,

increased PD-1 ligand expression, and further induction via

JAK2 in nodular sclerosing Hodgkin lymphoma and primary

mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-

Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA,

Homer H, et al. PD-L1 and PD-L2 Genetic Alterations Define

Classical Hodgkin Lymphoma and Predict Outcome. J Clin

Oncol. 2016;34(23):2690-7.

Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz

M, et al. Genomic imbalances including amplification of the

tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res.

;60(3):549-52.

Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, et al.

Cooperative epigenetic modulation by cancer amplicon genes.

Cancer Cell. 2010;18(6):590-605.

Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann

S, Mechtersheimer G, et al. TNFAIP3 (A20) is a tumor suppressor

gene in Hodgkin lymphoma and primary mediastinal B cell

lymphoma. J Exp Med. 2009;206(5):981-9.

Lake A, Shield LA, Cordano P, Chui DTY, Osborne J, Crae S, et

al. Mutations of NFKBIA, encoding IkBa, are a recurrent finding

in classical Hodgkin lymphoma but are not a unifying feature

of non-EBV-associated cases. Int J Cancer. 2009;125(6):1334-42.

Emmerich F, Theurich S, Hummel M, Haeffker A, Vry MS,

Döhner K, et al. Inactivating I kappa B epsilon mutations in

Hodgkin/Reed-Sternberg cells. J Pathol. 2003;201(3):413-20.

Tiacci E, Penson A, Schiavoni G, Ladewig E, Fortini E,

Wang Y, et al. New Recurrently Mutated Genes in Classical

Hodgkin Lymphoma Revealed by Whole-Exome Sequencing of

Microdissected Tumor Cells. Blood. 2016;128(22):1088.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligand

in Tolerance and Immunity. Annu Rev Immunol. 2008;26(1):677-

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura

H, et al. Engagement of the PD 1 Immunoinhibitory Receptor

by a Novel B7 Family Member Leads to Negative Regulation of

Lymphocyte Activation. J Exp Med. 2000;192(7):1027-34.

Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H,

Nishimura M. B7-H1 Expression on Non-Small Cell Lung Cancer

Cells and Its Relationship with Tumor-Infiltrating Lymphocytes

and Their PD-1 Expression. Clin Cancer Res. 2004;10(15):5094-

Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Scott

Webster W, et al. Costimulatory B7-H1 in renal cell carcinoma

subjects: Indicator of tumor aggressiveness and potential

therapeutic target. Proc Natl Acad Sci USA. 2004;101(49):17174-9.

Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et

al. Clinical Significance of Programmed Death-1 Ligand-1 and

Programmed Death-1 Ligand-2 Expression in Human Esophageal

Cancer. Clin. Cancer Res. 2005;11(8):2947-53.

Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T,

et al. Tumor Cell Expression of Programmed Cell Death-1

ligand 1 Is a Prognostic Factor for Malignant Melanoma. Cancer.

;116(7):1757-66.

Roosbroeck KV, Ferreiro JF, Tousseyn T, van der Krogt J-A,

Michaux L, Pienkowska-Grela B, et al. Genomic Alterations of

the JAK2 and PDL Loci Occur in a Broad Spectrum of Lymphoid

Malignancies. Genes Chromosom Cancer. 2016;55(5):428-41.

Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et

al. Targetable genetic features of primary testicular and primary

central nervous system lymphomas. Blood. 2016;127(7):869-81.

Cheng Z, Dai Y, Wang J, Shi J, Ke X, Fu L. High PD-L1 expression

predicts poor prognosis in diffuse large B-cell lymphoma. Ann

Hematol. 2018;97(6):1085-8.

Garaicoa FH, Roisman A, Arias M, Trila C, Fridmanis M, Abeldaño

A, et al. Genomic imbalances and microRNA transcriptional

profiles in patients with mycosis fungoides. Tumor Biol.

;37(10):13637-47.

Kinch A, Sundström C, Baecklund E, Backlin C, Daniel M, Enblad

G. Expression of PD-1, PD-L1, and PD-L2 in posttransplant

lymphoproliferative disorder after solid organ transplantation.

Leuk Lymphoma. 2019;60(2):376-84.

Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML,

et al. PD-L1 Expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin

Cancer Res. 2013;19(13):3462-73

Paydas S, Bağır E, Seydaoglu G, Ercolak V, Ergin M. Programmed

death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBVencoded

RNA (EBER) expression in Hodgkin lymphoma. Ann

Hematol 2015;94(9):1545-52.

Meignan M, Gallamini A, Haioun C. Report on the First

International Workshop on interim-PET-scan in lymphoma. Leuk

Lymphoma. 2009;50(8):1257-60.

Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation

of the diagnostic and prognostic value of PDL1 expression in

Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17-24.

Koh YW, Jeon YK, Yoon DH, Suh C, Huh J. Programmed death

expression in the peritumoral microenvironment is associated

with a poorer prognosis in classical Hodgkin lymphoma. Tumor

Biol. 2016;37(6):7507-14.

Hollander P, Kamper P, Ekstrom Smedby K, Enblad G,

Ludvigsen M, Mortensen J, et al. High proportions of PD-1

+ and PD-L1 + leukocytes in classical Hodgkin lymphoma

microenvironment are associated with inferior outcome. Blood

Adv. 2017;1(18):1427-39.

Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC,

Gjini E, et al. Topological analysis reveals a PD-L1-associated

microenvironmental niche for Reed-Sternberg cells in Hodgkin

lymphoma. Blood. 2017;130(22):2420-30.

Falzetti D, Crescenzi B, Matteuci C, Falini B, Martelli MF, Van Den

Berghe H, et al. Genomic instability and recurrent breakpoints are

main cytogenetic findings in Hodgkin’s disease. Haematologica.

;84(4):298-305.

M’Kacher R, Girinsky T, Koscielny S, Dossou J, Violot D,

Beron-Gaillard N, et al. Baseline and treatment-induced

chromosomal abnormalities in peripheral blood lymphocytes

of Hodgkin’s lymphoma patients. Int J Radiat. Oncol Biol Phys.

;57(2):321-6.

Barrios L, Caballin MR, Miro R, Fuster C, Berrozpe G, Subias A, et

al. Chromosome abnormalities in peripheral blood lymphocytes

from untreated Hodgkin’s patients. A possible evidence for

chromosome instability. Hum Genet. 1988;78(4):320-4.

Salas C, Niembro A, Lozano V, Gallardo E, Molina B, Sanchez

S, et al. Persistent genomic instability in peripheral blood

lymphocytes from Hodgkin lymphoma survivors. Environ. Mol.

Mutagen. 2012;53(4):271-80.

Mata E, Díaz-López A, Martín-Moreno AM, Sánchez-Beato M,

Varela I, Mestre MJ, et al. Analysis of the mutational landscape of

classic Hodgkin lymphoma identifies disease heterogeneity and

potential therapeutic targets. Oncotarget. 2017;8(67):111386-95.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Derechos de autor 2021 Médicas UIS

Descargas

Los datos de descargas todavía no están disponibles.